Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 20, 2025 578 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RedirecTT-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR The director’s cut: How Dr Catherine Elliott sees the future of... November 2, 2021 Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients... September 10, 2025 Medical Cannabis Formulation May Be Capable of Killing Breast Cancer Cells,... May 21, 2021 Data Shows Women Are Not Getting Access To An Important Part... July 30, 2021 Load more HOT NEWS The most important cancer research stories of 2022 FDA Grants Accelerated Approval to Lurbinectedin for Metastatic SCLC Cancer-Related Fatigue: What People With Cancer and Their Loved Ones Should... President’s Cancer Panel Report: Closing Gaps in Cancer Screening for All...
